Selection of a rare resistance profile in an HIV-1-infected patient exhibiting a failure to an antiretroviral regimen including tenofovir DF

J Clin Virol. 2005 Mar;32(3):241-4. doi: 10.1016/j.jcv.2004.05.020.

Abstract

The human immunodeficiency virus type 1 (HIV-1) resistance profile, K65R, K70E and M184V, on reverse transcriptase gene was associated with the virologic rebound consecutively to the switch of lopinavir/r to tenofovir DF in a stable regimen with nucleoside backbone of abacavir, lamivudine and didanosine. The high selective pressure on the same resistance pathway was probably associated with the loss of antiviral potency, even in well-controlled patient.

Publication types

  • Case Reports

MeSH terms

  • Adenine / analogs & derivatives*
  • Adenine / therapeutic use
  • Adult
  • Anti-HIV Agents / therapeutic use*
  • Didanosine / therapeutic use
  • Dideoxynucleosides / therapeutic use
  • Drug Resistance, Viral / genetics
  • Female
  • Gabon
  • HIV Infections / drug therapy
  • HIV Infections / virology*
  • HIV Reverse Transcriptase / genetics
  • HIV-1 / drug effects*
  • HIV-1 / genetics
  • Humans
  • Lamivudine / therapeutic use
  • Lopinavir
  • Microbial Sensitivity Tests
  • Mutation
  • Organophosphonates / therapeutic use*
  • Pyrimidinones / therapeutic use
  • Tenofovir
  • Viral Load

Substances

  • Anti-HIV Agents
  • Dideoxynucleosides
  • Organophosphonates
  • Pyrimidinones
  • Lopinavir
  • Lamivudine
  • Tenofovir
  • HIV Reverse Transcriptase
  • Adenine
  • Didanosine
  • abacavir